Form 4 for ORMP ORAMED PHARMACEUTICALS INC.
Accepted 2023-04-20 00:00:00 ET · period of report 2023-04-17 · accession 0001209191-23-024937 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-04-20 | 2023-04-17 | ORMP | Kidron Miriam | CSO, Dir | A - Grant | — | +213.0K | 414.7K | +106% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-04-17 | A | A | 213,000 | — | 414,666 | D | — | — | (F1) Represents Restricted Stock Units ("RSUs") that will vest in equal quarterly installments of 17,750 over a three year period starting May 1, 2023. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. |